[Chronic lymphocytic leukemia and the related disorders].
Karasawa
Masamitsu
M
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002869:Chromosome Aberrations; D015321:Gene Rearrangement; D006801:Humans; D007136:Immunoglobulins / Q000235:genetics; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics / Q000628:therapy; D009154:Mutation; D009367:Neoplasm Staging; D011995:Recombination, Genetic; D000069283:Rituximab; D013997:Time Factors; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007136:Immunoglobulins; D000069283:Rituximab; D014740:Vidarabine; C024352:fludarabine